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ABSTRACT
INTRODUCTION: Psoriasis is a chronic immune-mediated inflammatory disease. Human cathelicidin 
(hCAP18/LL37) has been elucidated recently as a modulator of inflammation in the affected skin. Vita-
min D may induce expression of this antimicrobial peptide. Our trial aimed to study the circulating level of 
hCAP18/LL-37 and to explore its relationship with the severity of psoriasis.
MATERIALS AND METHODS: 79 patients with moderate to severe psoriasis (PASI >10) were included in a 
retrospective analysis. Stored serum samples were used for assessment of 25-hydroxyvitamin D - 25(OH)D 
and to measure the circulating human cathelicidin (LL-37).
RESULTS: In a study group of 79 patients we assessed mean level of 25(OH)D of 30.25 nmol/l (95% CI 25.87 
– 34.62 nmol/l). Mean circulating cathelicidin was 27.17 ng/ml (95% CI 21.52 – 32.83 ng/ml). Only 8.9% of 
patients had LL-37 level > 54 ng/ml. Although circulating LL-37 was lower in severe psoriasis than in moder-
ate psoriasis (24.33 ng/ml vs. 31.14 ng/ml), the variation was nonsignificant. We further evaluated the asso-
ciation of LL-37 with both PASI score and 25(OH)D concentration in the subgroup of patients with vitamin 
D deficiency (n=39). It was interesting to find a significant correlation between the level of LL-37 and 25(OH)
D (r=0.38, p=0.017) and an inverse association between the level of LL-37 and PASI (r=-0.30, p=0.06).
CONCLUSION: In this pilot trial we assessed low serum levels of cathelicidin antimicrobial peptide in pa-
tients with psoriasis. LL-37 may be discussed as related to PASI and 25(OH)D in a subgroup of psoriatic pa-
tients with vitamin D deficiency.
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INTRODUCTION
Affected psoriatic skin has a characteristic ex-
cessive production of antimicrobial peptides (AMPs) 
like cathelicidin, beta-defensins and S-100 proteins. 
Typically, AMPs are small (12-15 amino acids) mole-
cules, having positive charge and amphipathic struc-
ture that can be found in all live organisms, like in-
sects, mammals and even plants (3). Humans contain 
only one cathelicidin family member called hCAP18/
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ation and treatment of psoriasis were included in the 
retrospective study. At hospital admission our pa-
tients gave informed consent about necessary proce-
dures. The patients with concomitant advanced kid-
ney and liver disease, malabsorption, biologic sys-
temic therapy and ultraviolet phototherapy, as well 
as vitamin D supplements intake were excluded from 
the study.
Psoriasis was diagnosed according to the clini-
cal presentation and the consistent morphology find-
ings in the skin biopsy. The type of psoriasis was cat-
egorized to: early type 1 (age below 40 at the initia-
tion of the disease) and late type 2 (patient’s age at 
diagnosis ≥40)(16)147 patients suffering from psoria-
sis, evaluation of the age of onset revealed two peaks, 
one occurring at the age of 16 years (female. The dis-
ease severity was assessed by the Psoriasis Area and 
Severity Index (PASI) and three grades were defined: 
mild psoriasis (PASI≤10), moderate one (PASI>10, 
≤30), and severe one (PASI > 30 up to 72). Also, we 
collected from medical records and analyzed the 
data about: age and gender of the patients; body mass 
index (BMI) and waist circumference (WC); lab re-
sults of the level of C-reactive protein (CRP); white 
blood count (WBC); glucose; cholesterol; triglycer-
ides; high density lipoprotein’s cholesterol (HDL-
c); creatinine and uric acid. Overweight and obe-
sity were defined based on the WHO definition of 
BMI≥25 and BMI≥30. We used the International Di-
abetes Federation features for central obesity: waist 
circumference ≥94 cm in Europid men and ≥80 cm 
for Europid women. 
Serum samples of the patients, stored in -20˚C, 
were used for an assessment of the level of the mark-
er for vitamin D status - 25-hydroxyvitamin D, 
25(OH)D, a principal circulating metabolite of vita-
min D and to measure the circulating human cathe-
licidin - LL-37. Serum levels of 25(OH)D were calcu-
lated by an immunofluorescent test (ADVIA Cen-
taur Vitamin D Total, Siemens) with assay range of 
3.7 to 150 ng/ml (9.3-375 nmol/l). The vitamin D sta-
tus was classified as deficiency (25(OH)D concentra-
tion <25 nmol/l), insufficiency (25 -75 nmol/l), suffi-
ciency (>75 to 250 nmol/l), and toxicity (>250 nmol/l) 
(17,18).  
The level of LL-37 was measured with a Human 
cathelicidin antimicrobial peptide ELISA Kit (CUS-
LL-37. The name hCAP18 refers to an 18kDa pep-
tide derived from the human Cationic Antimicrobi-
al Protein. LL-37 is a 37-amino acids peptide, start-
ing with a sequence of two ‘Leucine-Leucine’. LL-37 
was isolated for the first time from the polymorpho-
nuclear leukocytes. It is accepted that hCAP18 indi-
cates a pro-peptide, whereas LL-37 denotes a mature 
peptide, released from the C-terminus of hCAP18, 
having a potent and broad-spectrum of antimicro-
bial activity (4). LL-37, the human cathelicidin, rep-
resents “an elegant multifactorial effector molecule 
for innate immune defense of the skin” (5). Current-
ly, LL-37 has been elucidated as a modulator of the 
development of psoriasis (3). 
The concept of the important role of human 
cathelicidin was placed in 1997, by the report of 
Frohm et al. for the upregulation of LL-37 in psoriat-
ic epidermis as well as other skin inflammatory dis-
orders associated with disturbed barrier function of 
the epithelium. Authors hypothesized that LL-37 in-
duction enhances the antimicrobial defense capacity 
of the skin (6). Recently, it was proven that LL-37 can 
also modify immune and growth response and this 
diverse biological activity depends on the pattern of 
oligopeptides, derived from LL-37 (7-12). Lande et al. 
found that LL-37 can form a complex with particles 
of self-DNA, capable to activate plasmacytoid den-
dritic cells (pDCs) so that they recognize self-DNA 
through Toll-like receptor 9 and in that way drive 
an inflammation response in psoriasis (13). Activat-
ed pDCs can initiate a large production of interfer-
on-alfa (IFN-α), leading to a step-way process of my-
eloid dendritic cell (mDC) activation, Th1/Th17 dif-
ferentiation and consequent activation of the kerati-
nocytes (13,14).
The transcription of the cathelicidin gene is in-
duced by the binding of a bioactive form of vitamin 
D, 1, 25-dihydroxyvitamin D to the vitamin D recep-
tor. Dixon et al. suggested that the serum vitamin D 
may modulate the circulating level of LL-37 (15). 
Our study aimed to evaluate the serum level 
of vitamin D and human cathelicidin (LL-37) in pa-
tients with psoriasis and investigate the relationship 
to the severity of the disease
MATERIALS AND METHODS
79 consecutively admitted patients in the Clin-
ic of Dermatology and Venereology for initial evalu-
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ABIO, American Research Products Inc.) for the 
quantitative determination of endogenic human cat-
helicidin concentrations in serum, plasma, cell cul-
ture supernates, tissue homogenates, with a detection 
range of 0.45 ng/ml to 30 ng/ml and a minimum de-
tectable dose of LL-37 less than 0.11 ng/ml. 
The continuous variables were expressed as 
a mean value and standard deviation (SD) or as a 
mean value and a 95% confidence interval (CI). The 
differences between the variables were analyzed with 
the Mann-Whitney test and the Kruskal-Wallis test 
(in analyses of more than 2 independent variables). 
The relations between LL-37 level and 25(OH)D, as 
well as disease characteristics were assessed using 
the Spearman correlation coefficients. The software 
used for the analysis was GraphPad Prism, a demo 
6.07 version.
RESULTS
Our study included 43 male and 36 female pa-
tients with a mean age of 57 years (from 19 to 77 
years). Type 1, early psoriasis, was registered in 42 
patients (53.16%) and type 2, late onset psoriasis, 
in 37 patients (46.84%). The severity of the disease 
was defined as moderate (PASI >10, ≤30) in 33 pa-
tients (41.78%) and severe (PASI >30) in 46 patients 
(58.22%). The baseline characteristics of the study 
group are shown in Table 1.
The prevalence of overweight and obesity was 
36.7% and 35%, respectively. Central obesity was pre-
sented in 80.5% of female and in 37.2% of male pa-
tients. Analyzing comorbidities, we found a high fre-
quency of 33% of raised fasting plasma glucose (≥5.6 
mmol/l) and of 13.9% of diabetes type 2. Total blood 
cholesterol >5.2 mmol/l was observed in 44.3% of the 
study group, but most of them had a borderline el-
evation and only 7 patients (8.8%) had cholesterol 
above 6.2 mmol/l. Similarly, raised triglycerides, ≥1.7 
mmol/l and ≥2.2 mmol/l were assessed in 29.1% and 
15.2% of the patients, respectively. Reduced HDL-
c (<1.29 mmol/l in females and <1.03 in males) was 
found in 19 patients (24%). Elevated creatinine lev-
el corresponding to grade I chronic kidney failure 
was established in 8.9%. Only 4 patients (5%) had 
hyperuricemia. 
We assessed mean level of 25(OH)D of 30.25 
nmol/l (95% CI 25.87 – 34.62 nmol/l) in a study 
group of 79 patients with moderate to severe psori-
asis. A status of deficiency was registered in 39 pa-
tients (49.4%); insufficiency – in 37 patients (46.8%). 
Therefore, only 3 patients (3.8%) were classified as 
having vitamin D sufficiency. 
The mean observed circulating LL-37 in the se-
rum of our patients with psoriasis was 27.17 ng/ml 
(SD 25.25 ng/ml; 95% CI 21.52 - 32.83 ng/ml; range 
1.11 to 131.4 ng/ml). Very few - 8.9% of patients had 
LL-37 level > 54 ng/ml and only 3 patients appeared 
to have a maximum level of LL-37 >100 ng/ml (116, 
128 and 131 ng/ml, respectively). Figure 1 shows the 




Waist circumference, cm 98.90±23.02
CRP, mg/l 15.45±27.91
WBC count, x1012/l 7.56±2.23
Serum glucose, mmol/l 6.80±3.96
Serum cholesterol, mmol/l 5.02±1.03
Serum HDL cholesterol, mmol/l 1.43±0.55
Serum triglycerides, mmol/l 1.57±0.98
Serum uric acid, mmol/l 323.34±109.49
Serum creatinine, mmol/l 83.69±20.58
Early/Late type of psoriasis 42/37
PASI 32.85±12.18
Data have been presented as mean +/- SD. Abbreviations used in 
Table 1: SD (standard deviation); BMI (body mass index); CRP 
(C-reactive protein); WBC (white blood cells); HDL (High Density 
Lipoproteins); PASI (Psoriasis Area and Severity Index)
Table 1. Baseline characteristics of included patients with 
psoriasis (n=79)
Figure 1. Level of circulating LL-37, according to the age of 
patients with psoriasis
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(r= -0.16, p=0.15). We failed to establish an associ-
ation of the circulating LL-37 with 25(OH)D in the 
main group of 79 patients. There was a tendency for 
an inverse relationship between the LL-37 and PASI, 
but the level was not found to be significant. 
We further evaluated the association of LL-
37 with both PASI and 25(OH)D concentration in 
the subgroup of patients with vitamin D deficiency 
(n=39). It was interesting to find a significant correla-
tion between the level of LL-37 and 25(OH)D (r=0.38, 
p=0.017) and an inverse association between the level 
of LL-37 and PASI (r=-0.30, p=0.06). 
DISCUSSION
Psoriasis is a common immune-mediated skin 
disease. T-cells are involved in the pathogenesis, in-
filtrating the skin and secreting interferon-gamma 
and Th17 cytokines. An important fact is the chron-
ic overexpression of human antimicrobial peptide 
hCAP18/LL-37 in psoriatic plaques, mainly released 
by infiltrating neutrophils and by keratinocytes 
(6,13,14). LL-37 is able to trigger an activation of the 
innate immune cells (dendritic cells) and to break in-
nate tolerance to self-nucleic acids. Lande et al., in a 
recent study, suggested the possible role of LL-37 also 
as a T-cell autoantigen in psoriasis. LL-37 is shown to 
be recognized by circulating T-cells in up to 75% of 
patients with moderate-to-severe psoriasis. LL-37-re-
active T-cells produce Th17 cytokines and their de-
tection correlates with the severity of psoriasis (PASI) 
Table 2 shows the estimated levels of LL-37, ac-
cording to the gender of the patients, the type and 
severity grade of psoriasis and the vitamin D status. 
The subgroup analysis didn’t find a significant 
difference in the patients’ categories. Although cir-
culating, LL-37 was lower in severe psoriasis (PASI 
>30) than in moderate psoriasis, mean level of 24.33 
ng/ml and 31.14 ng/ml, the non-parametric t-test de-
fined the variation as nonsignificant, Figure. 2. 
No significant association was observed be-
tween the estimated serum LL-37 and the analyzed 
patients’ characteristics, such as: WC (r=0.07); BMI 
(r=0.06); CRP (r=0.10); 25(OH)D (r=0.05) and PASI 
Patient’s characteristics / 
subgroups
LL-37 (ng/ml)
Mean level (95% CI)
P
Gender: 
 ❖ Male (n=43)
 ❖ Female (n=36)
24.17 (16.33 – 32.01)




 ❖ Type 1 (n=42)
 ❖ Type 2 (n=37)
26.77 (20.64 – 32.90)
27.64 (17.41 – 37.86)
0.25,
ns
Severity grade of psoriasis
 ❖ Moderate (n=33)
 ❖ Severe (n=46)
31.14 (20.97 – 41.30)




 ❖ Insufficiency (n=37)
 ❖ Deficiency (n=39)
24.82 (16.41 – 33.23)
26.49 (19.79 – 33.19)
0.33
ns
Abbreviations used in Table 2: LL-37 (human cathelicidin); CI – confidence interval; P - level of significance; ns – nonsignificant
Table 2. Level of LL-37 in the subgroups of 79 patients with psoriasis
Figure 2. Level of circulating cathelicidin (LL-37) in the 
patients with moderate and severe grade of psoriasis
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(14). Considering the important role of LL-37 in the 
activation of both innate and T-cells immune cells in 
psoriasis, we designed that initial trial to test the cir-
culating level of LL-37 in clinical settings. 
Vitamin D deficiency and insufficiency in pa-
tients with psoriasis is a rising problem, document-
ed by numerous studies (15,19,20). In our reported 
group of 79 patients we observed a frequency of dis-
turbed vitamin D status of 96.2%. 
Experimental studies on human tissues (cul-
tivated epithelial cells, macrophages, neutrophils) 
demonstrated an increase of cathelicidin levels fol-
lowing administration of 1,25-dihydroxyvitamin D 
(21). Topical and oral vitamin D analogues can ini-
tiate a production of cathelicidines in the skin (22).
Few published clinical studies have investigat-
ed the relationship between the circulating 25(OH)D 
and the level of hCAP18/LL-37, showing contradicto-
ry results. The main opinion suggests a positive cor-
relation between vitamin D and the level of cathelici-
dins (15,23–25). For example, a trial in patients with 
severe septic condition revealed vitamin D deficien-
cy, low level of LL-37 (13.7±2.1 ng/mL), compared to 
circulating LL-37 in healthy controls (27.2±4.9 ng/
mL), mild positive correlation between LL-37 and 
25(OH)D, R=0.28 (24). The other studies argue on 
the existence of a relationship between the 25(OH)D 
and LL-37, as a trial in patients with pulmonary tu-
berculosis (26) and a study of dialysis patients (27). 
A possible explanation will be that LL-37 correlates 
with the bioavailable 25(OH)D, but not with the total 
25(OH)D (28)placebo-controlled, trial. SETTING: 
Medical and surgical ICUs of a single teaching hospi-
tal in Boston, MA. PATIENTS: Thirty adult ICU pa-
tients. INTERVENTIONS: Placebo (n = 10. Low LL-
37 was found in chronic dialysis patients(27), in neu-
tropenia of various aetiologies (29), chronic obstruc-
tive pulmonary disease (30)deterioration in health 
status and risk of death. The assessment of exacerba-
tion risk is important in the grading of COPD. The 
most common cause of COPD exacerbation is respi-
ratory tract infection. The only known human cathe-
licidin antimicrobial peptide, LL-37, play an impor-
tant role in innate defense against infection. Its gene 
expression is regulated by the bioactive form of vita-
min D. The objective of the present study was to ex-
plore the relationship between LL-37 plasma levels, 
vitamin D status and exacerbation risk in patients 
with COPD.\n\nMETHODS: COPD patients and 
normal subjects were recruited from Beijing Hospital 
for this study. COPD patients were divided into low 
risk group and high risk group according to the cri-
teria of GOLD strategy. The plasma concentrations 
of LL-37 were measured by ELISA technique to ex-
plore the difference in LL-37 levels between groups. 
The plasma levels of 25-hydroxy vitamin D [25(OH, 
in human immunodeficiency virus-1 infected in-
dividuals not receiving antiretroviral therapy (31) 
and in patients with ST - Segment Elevation Myo-
cardial Infarction (32). Much higher level of serum 
LL-37 was assessed in patients with chronic hepati-
tis B (174.66±100.7) ng/ml) and chronic hepatitis С 
(155.15±78.84 ng/ml); LL-37 concentration was not 
correlated with the documented vitamin D deficien-
cy in the studied population with viral hepatitis (33). 
The assessed blood LL-37 in psoriasis varies 
substantially. The median level of LL-37 was 11.78 
ng/ml (IQR 9.75 – 16.90 ng/ml) in 76 studied patients 
with plaque and guttate psoriasis (34). Another tri-
al assessed similar mean level of 18.16 ng/ml (range 
9.1 to 35.9 ng/ml) in 100 patients with psoriasis and 
co-morbidities; serum LL-37 was inversely correlat-
ed with 25(OH)D (35)a lot of co-morbidities (diabe-
tes, obesity, heart disease, etc.. Much higher concen-
trations of 970 ng/ml were investigated in 61 psoriat-
ic patients by Kanda et al. and the serum LL-37 did 
not correlate with the PASI score (36). The ultravio-
let B phototherapy lead to an increase of the circulat-
ing LL-37 (35)a lot of co-morbidities (diabetes, obesi-
ty, heart disease, etc..
In our study we observed a mean level of LL-37 
of 27.17 ng/ml with a minimum level of 1.11 ng/ml 
and maximum level of 131.40 ng/ml, but only 8.9% of 
our patients had a level of LL-37 > 54 ng/ml. There-
fore, we concluded of low circulating cathelicidin in 
our group patients with moderate to severe psoriasis. 
Systemic LL-37 levels are highly variable among 
subjects included as control groups of the different 
published studies (15,23–36)1,25-dihydroxyvitamin 
D, to the vitamin D receptor. Significant levels of the 
protein hCAP18/LL-37 are found in the blood and 
may protect against infection and/or sepsis. We hy-
pothesized that serum vitamin D levels may mod-
ulate the circulating levels of hCAP18. Only three 
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studies have shown a positive correlation between 
circulating 25-hydroxyvitamin D and hCAP18 lev-
els. Here we provide additional evidence for such 
a correlation in healthy, middle-aged adults.\n\
nFINDINGS: Serum levels of 25-hydroxyvitamin D 
[25(OH. Blood LL-37 is produced by a variety of cell 
types such as neutrophils, macrophages and epithe-
lial cells. Other factors that may affect the circulating 
LL-37 are a lack of standard method for ELISA test-
ing, variation by age, ethnicity, exposure to ultravio-
let light and pathogens inducing LL-37, such as viral 
or bacterial infections. Previous studies commented 
that low circulating LL-37 in severe infections may 
be due to a rapid binding of LL-37 peptide to serum 
lipoproteins, as an effective LL-37 scavenging mech-
anism (37)we postulated that this inhibition results 
from binding of LL-37 to unidentified proteins. An 
LL-37 binding plasma protein has now been isolat-
ed by affinity chromatography. SDS-polyacrylamide 
gel electrophoresis of proteins that bound to an LL-
37 column revealed one band with a molecular mass 
of about 26 kDa, and amino acid sequence analysis 
identified the protein as apolipoprotein A-I (apoA-I. 
In our analysis we failed to establish an association 
of LL-37 level with markers of existing infection, as 
CRP and WBC count. 
Bhan et al. hypothesized that a positive cor-
relation between LL-37 and 25(OH)D exists only 
in individuals with a vitamin D deficiency, stat-
ing a threshold of 32 ng/ml (80 nmol/l) below that 
a positive significant relationship of cathelicidin and 
25(OH)D can be observed (38). Authors suggest that 
the biological effect of vitamin D on blood levels of 
hCAP18/LL-37 may be initiated only in the presence 
of 25(OH)D sufficiency (15). 
In a subgroup analysis of 39 psoriatic patients 
with 25(OH)D < 25 nmol/l we found a significant 
correlation between the level of LL-37 and 25(OH)D 
(r=0.38, p=0.017) and an inverse association between 
the level of LL-37 and PASI (r=-0.30, p=0.06). Our 
study supports the concept of an association of LL-
37 and the severity of an immune-mediated disease, 
such as psoriasis. The relationship of LL-37 and PASI 
was demonstrated only in the patients with vitamin 
D deficiency. 
CONCLUSION
Our study could contribute to the hypothe-
sis considering the role of human cathelicidin, in-
nate immune peptide in the pathogenesis of psoria-
sis. Further studies are required to focus on tissue ex-
pression of LL-37. In regard to the immune-modulat-
ing potential of cathelicidin there is a need to assess 
its role in the biological therapy of psoriatic patients. 
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